Detalles de la búsqueda
1.
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Breast Cancer Res Treat
; 197(2): 355-368, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36409394
2.
Intraoperative central nipple biopsy in nipple-sparing mastectomy- A retrospective analysis of 211 patients.
Breast J
; 27(4): 363-368, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33619792
3.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
BMC Cancer
; 20(1): 286, 2020 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252684
4.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
BMC Cancer
; 20(1): 1091, 2020 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33176725
5.
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Int J Cancer
; 144(4): 877-885, 2019 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29992557
6.
Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
Oncologist
; 20(11): 1333-41, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26417039
7.
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Eur J Cancer
; 198: 113480, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38154393
8.
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.
Geburtshilfe Frauenheilkd
; 84(5): 459-469, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38817595
9.
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
Chemotherapy
; 59(5): 387-94, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24852315
10.
Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy.
Breast Care (Basel)
; 17(2): 130-136, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35702496
11.
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Eur J Cancer
; 172: 13-21, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728342
12.
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.
Geburtshilfe Frauenheilkd
; 82(10): 1055-1067, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36186151
13.
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
Eur J Cancer
; 155: 1-12, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34311211
14.
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
Breast Care (Basel)
; 15(1): 82-95, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32231503
15.
ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019: Commentary by the German panel of experts on the ABC5 voting results.
Geburtshilfe Frauenheilkd
; 80(6): 588-600, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32565549
16.
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Cancers (Basel)
; 12(10)2020 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33080911
17.
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Breast
; 54: 88-95, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32956934
18.
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Geburtshilfe Frauenheilkd
; 80(11): e289, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33262544
19.
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Geburtshilfe Frauenheilkd
; 80(11): 1134-1142, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33173241
20.
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
BMC Cancer
; 9: 38, 2009 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-19175937